Skip to main content

Incyte Corp(INCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low60.31
Day High61.87
Open:61.80
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
PR Newswire
Pancreatic Cancer Battle Boosted by $200M VC Firm
PR Newswire
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
The Globe and Mail
Incyte: Top 25 Undervalued S&P 500 Composite Index Stocks (INCY)
The Globe and Mail
Incyte: Top 25 Undervalued Nasdaq Composite Index Stocks (INCY)
The Globe and Mail
Incyte: Top 25 Undervalued Nasdaq Composite Index Stocks (INCY)

Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.